Prime Medicine (PRME) Cash from Operations (2021 - 2026)

Prime Medicine (PRME) has 6 years of Cash from Operations data on file, last reported at 42710000.0 in Q1 2026.

• Quarterly Cash from Operations rose 12.58% year-over-year to 42710000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 156417000.0 (down 50.38% YoY) and the FY2025 annual result came in at 162564000.0, down 32.31% from the prior year.
• Cash from Operations declined to 42710000.0 in Q1 2026, from 37256000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 16245000.0 in Q4 2024 to a low of 67707000.0 in Q1 2024.
• A 5-year average of 36786941.18 and a median of 40821000.0 in 2023 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2024 — Cash from Operations surged 137.03% — and 2025, when it plunged 329.34%.
• Tracing PRME's Cash from Operations over 5 years: stood at 30713000.0 in 2022, then plunged by 42.82% to 43864000.0 in 2023, then surged by 137.03% to 16245000.0 in 2024, then tumbled by 329.34% to 37256000.0 in 2025, then retreated by 14.64% to 42710000.0 in 2026.
• The last three Cash from Operations figures came in at 42710000.0 (Q1 2026), 37256000.0 (Q4 2025), and 35039000.0 (Q3 2025), per Business Quant data.